---
figid: PMC8293989__fphar-12-714483-g001
figtitle: 'Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between
  Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives'
organisms:
- Hepatitis B virus
- Human immunodeficiency virus
- Human T-cell leukemia virus type I
- Helicobacter pylori
- Akkermansia muciniphila
- Homo sapiens
- gut metagenome
- Camelus bactrianus
organisms_ner:
- Homo sapiens
- Camelus bactrianus
- Drosophila melanogaster
pmcid: PMC8293989
filename: fphar-12-714483-g001.jpg
figlink: /pmc/articles/PMC8293989/figure/F1/
number: F1
caption: PD-1 and PD-L1 Signaling Pathway ).
papertitle: 'Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between
  Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives.'
reftext: Yating Zhao, et al. Front Pharmacol. 2021;12:714483.
year: '2021'
doi: 10.3389/fphar.2021.714483
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.
keywords: immunotherapy | PD-1/PD-L1 | nivolumab | pembrolizumab | tislelizumab |
  atezolizumab | efficacy | safety
automl_pathway: 0.9315026
figid_alias: PMC8293989__F1
figtype: Figure
redirect_from: /figures/PMC8293989__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8293989__fphar-12-714483-g001.html
  '@type': Dataset
  description: PD-1 and PD-L1 Signaling Pathway ).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - APC
  - PROC
  - CD80
  - CD86
  - CD28
  - HLA-C
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - COL1A1
  - COL1A2
  - Apc
  - Apc2
  - Axn
  - Fs(3)Apc
  - Mhc
  - zip
  - Tcr
  - Col4a1
---
